1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Inflammatory Pain - Pipeline Review, H2 2014

Inflammatory Pain - Pipeline Review, H2 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 164 pages

Inflammatory Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Inflammatory Pain - Pipeline Review, H2 2014’, provides an overview of the Inflammatory Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammatory Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammatory Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammatory Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Inflammatory Pain - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Inflammatory Pain Overview 8
Therapeutics Development 9
Pipeline Products for Inflammatory Pain - Overview 9
Pipeline Products for Inflammatory Pain - Comparative Analysis 10
Inflammatory Pain - Therapeutics under Development by Companies 11
Inflammatory Pain - Therapeutics under Investigation by Universities/Institutes 15
Inflammatory Pain - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Inflammatory Pain - Products under Development by Companies 18
Inflammatory Pain - Products under Investigation by Universities/Institutes 21
Inflammatory Pain - Companies Involved in Therapeutics Development 22
Boehringer Ingelheim GmbH 22
Kyowa Hakko Kirin Co., Ltd. 23
Shionogi and Co., Ltd. 24
AstraZeneca PLC 25
MedImmune, LLC 26
Merck and Co., Inc. 27
Takeda Pharmaceutical Company Limited 28
Glenmark Pharmaceuticals Ltd. 29
Pfizer Inc. 30
Evotec AG 31
Anavex Life Sciences Corp. 32
Array BioPharma Inc. 33
Pluristem Therapeutics Inc. 34
BCN Peptides, S.A. 35
Upsher-Smith Laboratories, Inc. 36
Grunenthal GmbH 37
Integral Molecular, Inc. 38
AngioChem Inc. 39
Asahi Kasei Pharma Corp. 40
Hydra Biosciences, Inc. 41
NeurAxon, Inc. 42
Cara Therapeutics, Inc. 43
CLL Pharma 44
Dompe Farmaceutici S.p.A. 45
Lohocla Research Corporation 46
MAKScientific, LLC 47
RaQualia Pharma Inc. 48
Sunovion Pharmaceuticals Inc. 49
Adynxx, Inc. 50
Kareus Therapeutics, SA 51
AnaBios Corporation 52
Creabilis SA 53
Istituto Italiano di Tecnologia 54
Infirst Healthcare Limited 55
AbbVie Inc. 56
Epirus Biopharmaceuticals, Inc. 57
Inflammatory Pain - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 63
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
grapiprant - Drug Profile 71
Z-944 - Drug Profile 73
DD-04107 - Drug Profile 74
S-120083 - Drug Profile 75
SYN-1002 - Drug Profile 76
GBR-900 - Drug Profile 77
Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 78
Small Molecule to Antagonize Bradykinin Receptor B1 for Pain - Drug Profile 79
OX-MPI - Drug Profile 80
Small Molecule to Inhibit nNOS/iNOS for Inflammatory Pain - Drug Profile 81
HC-030031 - Drug Profile 82
CR-845 - Drug Profile 83
Small Molecule to Antagonize TrkA for Inflammatory Pain - Drug Profile 85
ANAVEX-1079 - Drug Profile 86
ANG-2002 - Drug Profile 87
AMAP-102 - Drug Profile 88
CT-340 - Drug Profile 90
RQ-00000008 - Drug Profile 91
CR-701 - Drug Profile 92
Small molecules To Inhibit CDK9 for Central Nervous System and Immunology - Drug Profile 93
AK-106 - Drug Profile 94
Z-212 - Drug Profile 95
Stem Cell Therapy for Neuropathic and Inflammatory Pain - Drug Profile 96
conolidine - Drug Profile 97
AYX-3 - Drug Profile 98
Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile 99
Biologic 2 for Central Nervous System - Drug Profile 100
Drugs to Inhibit SRC-ND2 Interaction for Neuropathic Pain and Inflammatory Pain - Drug Profile 101
Small Molecule Targeting Cannabinoid Receptor For Inflammatory Pain - Drug Profile 102
AR-786 - Drug Profile 103
AZ-1 - Drug Profile 104
AZ-2 - Drug Profile 105
Small Molecule to Inhibit FAAH for Pain - Drug Profile 106
Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 107
ZJ-43 - Drug Profile 108
Drug to Inhibit Glutaminase for Inflammatory Pain - Drug Profile 109
MK-8825 - Drug Profile 110
MAK-2124 - Drug Profile 111
A-836339 - Drug Profile 112
Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile 113
ibuprofen - Drug Profile 114
Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders - Drug Profile 115
PNU-120596 - Drug Profile 116
AB-144 - Drug Profile 117
NET-END - Drug Profile 118
PF-3845 - Drug Profile 119
BIBN-4096BS - Drug Profile 120
Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 121
Small Molecules to Inhibit TRPA1 and TRPV1 for CNS - Drug Profile 122
URB-937 - Drug Profile 124
BBI-11008 - Drug Profile 125
A-1048400 - Drug Profile 126
NH-34 - Drug Profile 127
K-685 - Drug Profile 128
ET-1 - Drug Profile 129
GRTTA-2210 - Drug Profile 130
RO-656570 - Drug Profile 131
FV-082 - Drug Profile 132
FV-137 - Drug Profile 133
Small Molecules to Antagonize Cav3.2 for Pain - Drug Profile 134
DF-2593A - Drug Profile 135
UNC-3230 - Drug Profile 136
Kindolor - Drug Profile 137
Nav 1.7 Blocker Program - Drug Profile 139
Nav1.8 Sodium Channel Blocker For Pain - Drug Profile 140
Biologic 1 for Central Nervous System - Drug Profile 141
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 142
Inflammatory Pain - Recent Pipeline Updates 143
Inflammatory Pain - Dormant Projects 151
Inflammatory Pain - Discontinued Products 152
Inflammatory Pain - Product Development Milestones 153
Featured News and Press Releases 153
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 159
Disclaimer 159

List of Tables

Number of Products under Development for Inflammatory Pain, H2 2014 14
Number of Products under Development for Inflammatory Pain - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Development, H2 2014 22
Products under Development by Companies, H2 2014 23
Products under Development by Companies, H2 2014 (Contd..1) 24
Products under Development by Companies, H2 2014 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2014 26
Inflammatory Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014 27
Inflammatory Pain - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 28
Inflammatory Pain - Pipeline by Shionogi and Co., Ltd., H2 2014 29
Inflammatory Pain - Pipeline by AstraZeneca PLC, H2 2014 30
Inflammatory Pain - Pipeline by MedImmune, LLC, H2 2014 31
Inflammatory Pain - Pipeline by Merck and Co., Inc., H2 2014 32
Inflammatory Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 33
Inflammatory Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 34
Inflammatory Pain - Pipeline by Pfizer Inc., H2 2014 35
Inflammatory Pain - Pipeline by Evotec AG, H2 2014 36
Inflammatory Pain - Pipeline by Anavex Life Sciences Corp., H2 2014 37
Inflammatory Pain - Pipeline by Array BioPharma Inc., H2 2014 38
Inflammatory Pain - Pipeline by Pluristem Therapeutics Inc., H2 2014 39
Inflammatory Pain - Pipeline by BCN Peptides, S.A., H2 2014 40
Inflammatory Pain - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 41
Inflammatory Pain - Pipeline by Grunenthal GmbH, H2 2014 42
Inflammatory Pain - Pipeline by Integral Molecular, Inc., H2 2014 43
Inflammatory Pain - Pipeline by AngioChem Inc., H2 2014 44
Inflammatory Pain - Pipeline by Asahi Kasei Pharma Corp., H2 2014 45
Inflammatory Pain - Pipeline by Hydra Biosciences, Inc., H2 2014 46
Inflammatory Pain - Pipeline by NeurAxon, Inc., H2 2014 47
Inflammatory Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 48
Inflammatory Pain - Pipeline by CLL Pharma, H2 2014 49
Inflammatory Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 50
Inflammatory Pain - Pipeline by Lohocla Research Corporation, H2 2014 51
Inflammatory Pain - Pipeline by MAKScientific, LLC, H2 2014 52
Inflammatory Pain - Pipeline by RaQualia Pharma Inc., H2 2014 53
Inflammatory Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 54
Inflammatory Pain - Pipeline by Adynxx, Inc., H2 2014 55
Inflammatory Pain - Pipeline by Kareus Therapeutics, SA, H2 2014 56
Inflammatory Pain - Pipeline by AnaBios Corporation, H2 2014 57
Inflammatory Pain - Pipeline by Creabilis SA, H2 2014 58
Inflammatory Pain - Pipeline by Istituto Italiano di Tecnologia, H2 2014 59
Inflammatory Pain - Pipeline by Infirst Healthcare Limited, H2 2014 60
Inflammatory Pain - Pipeline by AbbVie Inc., H2 2014 61
Inflammatory Pain - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 62
Assessment by Monotherapy Products, H2 2014 63
Number of Products by Stage and Target, H2 2014 66
Number of Products by Stage and Mechanism of Action, H2 2014 70
Number of Products by Stage and Route of Administration, H2 2014 73
Number of Products by Stage and Molecule Type, H2 2014 75
Inflammatory Pain Therapeutics - Recent Pipeline Updates, H2 2014 148
Inflammatory Pain - Dormant Projects, H2 2014 156
Inflammatory Pain - Discontinued Products, H2 2014 157

List of Figures
Number of Products under Development for Inflammatory Pain, H2 2014 14
Number of Products under Development for Inflammatory Pain - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Products, H2 2014 22
Assessment by Monotherapy Products, H2 2014 63
Number of Products by Top 10 Target, H2 2014 64
Number of Products by Stage and Top 10 Target, H2 2014 65
Number of Products by Top 10 Mechanism of Action, H2 2014 68
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 69
Number of Products by Top 10 Route of Administration, H2 2014 72
Number of Products by Stage and Top 10 Route of Administration, H2 2014 73
Number of Products by Top 10 Molecule Type, H2 2014 74
Number of Products by Stage and Top 10 Molecule Type, H2 2014 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Pharmaceutical
Chronic Pain
R&D

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.